Along with molecular prognostic biomarkers, programmed death‐1 (PD‐1)/program death ligand‐1 (PD‐L1) immunohistochemistry (IHC) has become an integral part of standard treatment regimens for NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.